The future is HERE!

Okay, well, maybe not quite, but its closer... LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia | LogicBio Therapeutics, Inc. - Company believes dosing represents first in vivo gene editing therapy delivered systemically to a pediatric patient - Clinical trial designed to treat patients as young as 6 months old with LB-001 based on proprietary GeneRide™ platform - Company remains on track to announce update on enrollment, investor.logicbio.com (Just as an FYI, I don't represent this company in any way, but I couldn't find any non-company releases on the SUNRISE trial) Who knows if this will actually work, but I think gene-editing for congenital diseases is really the wave of the future in pediatrics. The highest mortality in pediatrics in... Read more
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pediatrics Source Type: forums